Coherus BioSciences (CHRS): Partnership Likely in 2H’17 - Citi

Citi analyst, Mohit Bansal, reiterated his Buy rating on shares of Coherus Biosciences (NASDAQ: CHRS) and sees $4-$8/sh upside for the company due to PTAB’s decision in favor of CHRS in the Humira ‘135 patent IPR case.

The analyst believes this win makes Humira's biosimilar launch based on the company's technology is more likely since the ‘135 patent was the key patent in Humira’s patent defense.

The next key catalyst for the company is the BSUFA decision on the Neulasta biosimilar by June 9, 2017. The analyst sees the stock trading close his target price of $38/sh.

price target of $38.00

For an analyst ratings summary and ratings history on Coherus Biosciences click here. For more ratings news on Coherus Biosciences click here.

Shares of Coherus Biosciences closed at $22.05 yesterday.

You May Also Be Interested In

• Morgan Stanley Downgrades Qifu Technology (QFIN) to Equalweight
• Bank of Nova Scotia (BNS:CN) (BNS) PT Raised to Cdn$152 at Keefe, Bruyette & Woods
• MongoDB (MDB) PT Raised to $465 at DA Davidson Ahead of Q2 Results